Source: International Congress 2019 – From biomarkers to treatment of immune-mediated interstitial lung disease: what’s new?
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Alberti (Buenos Aires, Argentina), V. Wolff (Santiago de Chile, Chile), F. Reyes (Santiago de Chile, Chile), E. Juarez Leon (Mexico DF, Mexico), V. Leiva (Santiago de Chile, Chile), G. Carballo (Buenos Aires, Argentina), J. Rojas Serrano (Mexico DF, Mexico), M. Mejía (Mexico DF, Mexico), L. Fassola (Buenos Aires, Argentina), F. Caro (Buenos Aires, Argentina), M. Florenzano (Santiago de Chile, Chile), F. Paulin (Buenos Aires, Argentina). Variables associated with functional improvement in patients with interstitial lung disease and myositis related antibodies: Results from a multicentric Latin American study.. 5194

Member's Comments

No comment yet.

Related content which might interest you: Multicentric Latin American study of 211 patients with Interstitial lung disease and myositis related antibodies Source: International Congress 2019 – Assessment and management of immune-mediated interstitial lung diseases Year: 2019 Rheumatoid arthritis-related interstitial lung disease (RA-ILD): Clinical, functional features, and variables associated poor initial prognosis in a chilean cohort Source: Virtual Congress 2020 – Clinical aspects and new treatment strategies for rare interstitial lung diseases in adults and children Year: 2020 Interstitial pneumonia with autoimmune features associated with myositis autoantibodies: clinical characteristics from a multicenter Latin-American cohort. Source: International Congress 2019 – Immune-mediated interstitial lung diseases: from bench to bedside Year: 2019 CPOD and lung function parameters as predictors of mortality: Results from the Latin American PLATINO cohort study Source: International Congress 2014 – Longitudinal studies of respiratory disease Year: 2014 PROOF-registry: A prospective observational registry to describe the disease course and outcomes of IPF patients in a real-world clinical setting- An interim report Source: International Congress 2015 – IPF: clinical aspects Year: 2015 Late Breaking Abstract - A composite serum biomarker index for the diagnosis of systemic sclerosis associated interstitial lung disease: a multicentre, observational, cohort study Source: Virtual Congress 2021 – New approaches to diagnostic and prognostic evaluation of interstitial lung diseases of known causes Year: 2021 PROOF-registry: A prospective observational registry to describe the disease course and outcomes of idiopathic pulmonary fibrosis patients in a real-world clinical setting Source: International Congress 2014 – ILDs 6 Year: 2014 Physical activity and clinical outcomes in patients with interstitial lung disease: how large is the impairment? – Preliminary results Source: International Congress 2018 – Chronic respiratory disease : determinants of physical activity in patients Year: 2018 Clinical features and outcomes of patients with myositis associated-interstitial lung disease Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases Year: 2021 Progression to a severe form of COVID-19 among patients with chronic respiratory diseases: a French multicentric study. Source: Virtual Congress 2021 – Epidemiology and burden of tuberculosis and other lung diseases Year: 2021 Outcomes of patients with progressive fibrosing interstitial lung disease (PF-ILD) – data from a prospective ILD registry Source: Virtual Congress 2021 – The future of idiopathic pulmonary fibrosis Year: 2021 Symptoms and quality of life in relation to lung function and comorbidities in patients with idiopathic pulmonary fibrosis: INSIGHTS-IPF registry Source: International Congress 2016 – IPF clinical Year: 2016 Respiratory medication use, lung function, and prior diagnosis of obstructive lung disease in five Latin American cities: the PLATINO study Source: Annual Congress 2008 - Epidemiology of respiratory symptoms and COPD Year: 2008 Clinical characteristics and determinants of exacerbation in Japanese patients with COPD: Hokkaido COPD cohort study results Source: Annual Congress 2012 - COPD exacerbation Year: 2012 Predicting mortality in idiopathic pulmonary fibrosis. Which parameters should be used to determine eligibility for treatment? Analysis of a UK prospective cohort Source: International Congress 2016 – The best is yet to come in terms of lung function Year: 2016 Interims analysis of the EXCITING-ILD registry (registry for exploring clinical and epidemiological characteristics of interstitial lung diseases) Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016 Treatment dilemmas in sarcoidosis - a retrospective cohort study Source: Annual Congress 2013 –Sarcoidosis and other granulomatosis Year: 2013 A large cohort study of clinical outcomes and prognostic predictors in patients with acute exacerbation of idiopathic pulmonary fibrosis Source: International Congress 2014 – IPF and surroundings Year: 2014 Efficacy of rituximab in patients with connective tissue disease associated interstitial lung disease: Preliminary results in safety and clinical response Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities Year: 2012 Nutrition-related factors associated with waiting list mortality in patients with interstitial lung disease: a retrospective cohort study Source: International Congress 2019 – Lung transplantation: from bench to bedside Year: 2019